US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

33.36 -3.29 (-8.98%)
Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Castle Biosciences, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
From Castle Biosciences Inc.
Via Business Wire
News headline image
Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Castle Biosciences Inc.
Via Business Wire
News headline image
Recap: Castle Biosciences Q4 Earnings ↗
 
Via Benzinga
News headline image
Earnings Preview For Castle Biosciences ↗
 
Via Benzinga
News headline image
Castle Biosciences Announces Updates to its Board of Directors
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
From Castle Biosciences Inc.
Via Business Wire
News headline image
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
From Castle Biosciences Inc.
Via Business Wire
News headline image
Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
From Castle Biosciences Inc.
Via Business Wire
News headline image
New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
From Castle Biosciences Inc.
Via Business Wire
News headline image
In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups
From Castle Biosciences Inc.
Via Business Wire
News headline image
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results
From Castle Biosciences Inc.
Via Business Wire
News headline image
Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024
From Castle Biosciences Inc.
Via Business Wire
News headline image
New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences’ DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results
From Castle Biosciences Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Castle Biosciences Inc.
Via Business Wire
News headline image
Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year
From Castle Biosciences Inc.
Via Business Wire
News headline image
Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Present at Upcoming Investor Conferences
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas
From Castle Biosciences Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >